8:00 am
Morning Refreshments

8:30 am Chair’s Opening Remarks


8:45 am Panel Discussion: Exploring the Link Between Biomarker Changes & Clinical Efficacy to Augment Implementation


  • Understanding the steps to be taken for validating biomarkers in research
  • Discussing the mismatch between biomarker use and therapeutic effect and potential solutions
  • Identifying the best avenues for quantitative markers that will add value to clinical studies

9:15 am High Throughput Platform for Rapid Screening of Compounds on Over 3000 Patients’ Derived Neurons in 30 Minutes


*Speaker to be confirmed, Ananda Devices

  • Uncovering robust compound screening on patients’ derived neurons
  • Revealing rapid evaluation of compounds’ toxicity and efficacy in Alzheimer’s Disease models
  • Investigating phenotypic markers of degeneration and regeneration

9:45 am
Speed Networking


This session is a great opportunity to introduce yourself to Alzheimer’s and Parkinson’s Disease experts from leading biopharma. This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the neurodegenerative disorders and establish meaningful business relationships.

9:45 am Outlining the Immuno-Dementia Hypothesis as a Foundation of Alzheimer’s Drug Discovery

  • Elena Dale Head of Biology, Center for Genetics Guided Dementia Discovery, Eisai


  • Exploring the immune-dementia hypothesis: public data and resources available
  • Assessing ability to identify new targets against Alzheimer’s Disease
  • Outlining strategies for future Alzheimer’s drug discovery

10:15 am
Morning Break

DISCOVERY & PRE-CLINICAL TRACK Novel Modelling Methods to Bolster Recapitulation of the CNS

11:15 am Human in vitro Disease Modeling – Development of Firstin- Class iPSC Models of Endogenous Tau Aggregation

  • Justine Manos Principal Scientist II, Tau Pathobiology, Abbvie Inc.


  • Optimization and QC of a well-known differentiation protocol improve robustness and reproducibility
  • Development of tau seeding models using AD brain-derived or recombinant tau seeds demonstrates that successful templating of endogenous tau requires compatibility between neuronal tau and exogenous seeds
  • In vitro endogenous tau aggregation is neuron subtype-specific, mimicking selective vulnerability observed in AD

11:45 am Advancing Neurodegenerative Drug Discovery with a New Class of Consistent, Scalable Human iPSC Derived cells


*Speaker to be confirmed, bit.bio

  • Discovering how next generation precision reprogramming technology, opti-ox(TM), is overcoming the inefficiencies and inconsistencies of current cell generation methods
  • Understanding how precision reprogramming is powering a new class of rapidly maturing, consistent and scalable human iPSC-derived cells (glutamatergic neurons, GABAergic neurons and microglia) and associated disease models for neurodegenerative disorders such as Gaucher’s, Huntington’s and Parkinson’s disease
  • Exploring insights into CNS drug discovery case studies: Compatibility of ioGlutamatergic Neurons for high throughput screening and the application of optiox powered GBA and Parkinson’s disease models in functional phenotypic screens

11:55 am Advancing NHP Models for Synucleinopathies: Precise Mapping of Pathological

  • Jeffrey Kordower Professor & Founding Director, ASU-Banner Neurodegenerative Disease Research Center, Rush University Medical Center


  • Using AAVs to express α-synucelin in NHP models
  • Monkey models of Tau aggregation propagated via AAV injections on Tau mutations
  • Monitoring and validating neurodegeneration in NHPs

11:55 am Evaluating In Vivo Rodent Models for Parkinson’s Disease: Current Progress and New Directions

  • Kelly Glajch Associate Scientific Director, Neurodegenerative Disease Research Unit, Biogen


  • Summary of in vivo rodent models in the PD field
  • Strengths of current models and how to best use them for decision making in drug development
  • Highlight gaps in the current models and opportunities for improvement

TRANSLATIONAL & CLINICAL TRACK Mapping Clinical Study Design for Efficient Timelines in High Investment Neurodegenerative Trials

11:15 am Strategies in Patient Selection for Your Therapeutic: Applying Biomarker Advances to Identify Appropriate Pathology by Target


  • Combining data science and genetics expertise to identify patients most likely to respond to treatment
  • Constructing patient selection algorithms using public and private data sets
  • Applying technology to ‘Phase 0’ trials of LRRK2

11:45 am Opportunities to Expand the Role of Patients in Drug Development for Alzheimer’s & Parkinson’s disease

  • Diane Stephenson Executive Director, Critical Path for Parkinson's, Critical Path Institute


  • Identifying stages along the drug development pipeline to incorporate the voice of patients
  • Integrating the patient voice into the advancement of digital health technologies as drug development tools in clinical trials
  • Looking to the future: how can we predict the placebo effect in future trials?

12:15 pm Clinical Roundtable Discussion


Join conversations with your translational and clinical peers to discuss challenges and opportunities of neurodegenerative clinical trials. Join tables led by clinical experts to discuss:

  • Patient Selection & Clinical Trial Design
  • Implementing Biomarkers & Functional Endpoints
  • Overcoming Commercial Challenges

12:45 pm
Lunch & Networking

DISCOVERY & PRE-CLINICAL TRACK Biology & Beyond – Understanding the Fundamentals to Map Future Pathological Targets in Alzheimer’s

1:45 pm Neuroinflammation: Microglia Phenotypes & Modulation Avenues for Developing Effective Complimentary Therapies

  • Anindya Sen Executive Director - Preclinical Research & Development, Prevail Therapeutics


  • Gene Therapy for Alzheimer’s Disease
  • AAV capsid-based microglia targeting
  • TREM2, a therapeutic target for AD and ALSP

2:15 pm Preclinical Roundtable Discussion


Join conversations with your fellow peers to discuss the benefits and challenges of neurodegenerative disease models. Join tables discussing sourcing, reproducibility, novel innovations and translation

TRANSLATIONAL & CLINICAL TRACK Upcoming Applications in Alzheimer’s Disease – Varying Strategies to Approach Successful Treatment

1:45 pm Gene Therapy for Alzheimer’s: APOE2 AAV Delivery Enabling Increase Potency through the Brain Barriers to Maximise Effect

  • Jay Barth Chief Medical Officer, Lexeo Therapeutics


  • Combining data science and genetics expertise to identify patients most likely to respond to treatment
  • Constructing patient selection algorithms using public and private data sets
  • Applying technology to ‘Phase 0’ trials of LRRK2

2:15 pm Exploring a Diverse Portfolio of Clinical Therapeutics Venturing Beyond Amyloid Candidates

  • Meriel Owen Associate Director, Search and Evaluation, Alzheimer's Drug Discovery


  • Outlining ADDF’s diverse portfolio of over 30 clinical trials in dementia
  • Using biology of aging as a foundation for our therapeutic strategy
  • Highlighting diversity of targets, drug modalities and drug status (repurposing vs. novel)

2:45 pm
Afternoon Break & Networking


3:45 pm Panel Discussion: The Amyloid Hypothesis – Dead or Alive?


  • Critically evaluating readouts from recent studies to justify the future of amyloid-related drugs
  • Exploring rationale behind study design choices and potential improvements to inform continuing practice
  • Discussing developments in historical data and likely implications for the Alzheimer’s field

4:15 pm The Importance of Data and Partnerships in Accelerating Neurodegeneration Clinical Trials

  • Gayle Wittenberg Vice President - Neuroscience Data Science & Digital Health, Janssen


  • Today’s challenges in clinical development for neurodegenerative diseases addressable through data, across modalities
  • Approaches to integrating external data into clinical development programs to ensure effective and appropriate use
  • Mapping the future of collaborative data partnerships to catapult clinical trials into the future

4:45 pm Chair’s Closing Remarks

5:00 pm
Scientific Poster Session


Continue networking after the presentations and share your work with fellow neurodegenerative experts to fuel future collaborations in the space

6:00 pm End of Conference Day One